Tb-PSMA-I&T Radionuclide Before Radical Prostatectomy in Patients With Locally Advanced Prostate Cancer - TbeforePROST Trial.

This is a multi-disciplinary collaboration between urologists, oncologists and nuclear medicine physicians from Beilinson hospital at Rabin Medical Center to address the major therapeutic challenge of locally advanced prostate cancer. Our aim is to evaluate the use of a novel treatment (Tb-PSMA) prior to the surgical removal of the prostate. This treatment has already shown initial promising results in patients with metastatic prostate cancer but has never been tested for locally advanced disease before surgery.

Trial Details

NCT ID
NCT07208240
Phase
PHASE1 / PHASE2
Sponsor
Rabin Medical Center
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Tb-PSMA-I&T (Tb-PSMA)
Locations (sample)
  • Petah Tikva, Israel|32.0888,34.88666

Key Eligibility Criteria

  • Male aged 18 years and older.
  • Patients with high-risk localized prostate cancer (cT3/4 and/or Gleason score ≥ eight and/or prostate biopsy or PSA ≥ 20 ng/dl)
  • High PSMA expression was confirmed according to PROMISE V2 8
  • Patients should have an Eastern Cooperative Oncology Group (ECOG) performance status score of 1 or lower and a life expectancy of \> 10 years.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →